- GenScript receives MSCI ESG A rating upgrade for its sustainability efforts.
GenScript Biotech Corporation has been upgraded to an A rating in its Environmental, Social, and Governance (ESG) score by MSCI, a globally respected rating agency.
MSCI evaluates thousands of companies globally, assessing their ESG performance and risk management. The agency’s ratings are widely regarded in international financial markets. GenScript’s improved rating is a recognition of the company’s progress over the past year in areas such as corporate governance, product safety, and environmental protection.
The company has taken several steps to enhance its ESG management, including forming a dedicated ESG team and collaborating with research institutions worldwide. “The A rating from MSCI is a significant recognition of our improvement in ESG performance,” said Sherry Shao, Rotating CEO of GenScript. “We believe integrating ESG principles strengthens our resilience and supports long-term success.”
In 2024, GenScript advanced its ESG commitments by joining the Science Based Targets initiative (SBTi) and submitting carbon reduction targets to address climate change. The company also received a bronze rating from EcoVadis for its supply chain management and workplace practices.